Pathology: la/mBC - HR-positive - 1st line (L1);
| la/mBC - HR-positive - 1st line (L1) | |||||||
| MONARCH 3, 2017 | MonarchE, 2021 | PENELOPE-B, 2021 | PALOMA-1, 2016 | PALOMA-2, 2016 | MONALEESA-2, 2016 | ||
| palbociclib plus letrozole | 2 | T1 | T1 | ||||
| abemaciclib plus endocrine therapy | 1 | T1 | |||||
| palbociclib plus endocrine therapy | 1 | T1 | |||||
| abemaciclib plus aromatase inhibitor | 1 | T1 | |||||
| ribociclib plus letrozole | 1 | T1 | |||||
| endocrine therapy | 0 | T0 | T0 | ||||
| aromatase inhibitor | 0 | T0 | |||||
| letrozole | 0 | T0 | T0 | T0 | |||